Foundation Medicine Receives Medicare Payment in Non-Small Cell Lung Cancer under a Local Coverage Determination for FoundationOne®, the Company's Comprehensive Genomic Profiling Assay
"Coverage and payment for FoundationOne under Palmetto GBA's LCD is a positive step toward advancing access to precision medicines for individuals living with non-small cell lung cancer," said
About
Cautionary Note Regarding Forward-Looking Statements for
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding reimbursement of the Company's comprehensive genomic profiling assays, the benefits provided by an FDA-approved and CMS-covered version of the Company's universal companion diagnostic test, and progress with the Parallel Review process with FDA and CMS; the scope and timing of any approval of FoundationOne as a medical device by FDA and any potential national coverage decisions by CMS; and strategies for achieving Medicare coverage decisions at the local or national level and new and expanded coverage from third-party payers. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include the risks that
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302006398/en/
Media Contact:
pr@foundationmedicine.com
or
Investor Contact:
ir@foundationmedicine.com
Source:
News Provided by Acquire Media